

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

**FORM 8-K**

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **July 23, 2007**

**CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.**  
*(Exact Name of Registrant as Specified in Its Charter)*

**Delaware**  
*(State or Other Jurisdiction of Incorporation)*

**000-51477**

*(Commission File Number)*

**20-2903562**

*(IRS Employer Identification No.)*

**No. 2, Jing You Road  
Kunming National Economy &  
Technology Developing District  
People's Republic of China 650217**

*(Address of Principal Executive Offices)*

**N/A**

*(Zip Code)*

**0086-871-728-2628**

*(Registrant's Telephone Number, Including Area Code)*

*(Former Name or Former Address, if Changed Since Last Report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## **Item 2.02 Results of Operations and Financial Condition**

On July 23, 2007, China Shenghuo Pharmaceutical Holdings, Inc. (the “Company”) issued a press release announcing its preliminary second quarter 2007 results and projections for fiscal year 2007 and 2008. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference.

## **Item 7.01 Regulation FD Disclosure**

On July 23, 2007, the Company issued a press release announcing its preliminary second quarter 2007 results and projections for fiscal year 2007 and 2008. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference.

The information in this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

## **Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1                      Press Release Dated July 23, 2007.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHINA SHENGHUO PHARMACEUTICAL HOLDINGS,  
INC.

Date: July 23, 2007

By: /s/ Gui Hua Lan

---

Name: Gui Hua Lan  
Title: Chief Executive Officer